Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Shindo, Koji ^a,c   Aishima, Shinichi ^a   Ohuchida, Kenoki ^a   Fujiwara, Kenji ^a,c   Fujino, Minoru ^a   Mizuuchi, Yusuke ^a,c   Hattori, Masami ^a   Mizumoto, Kazuhiro ^a,b   Tanaka, Masao ^a   Oda, Yoshinao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Cancer associated fibroblast; Pancreatic cancer; Podoplanin

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GELATINASE A; PODOPLANIN; STROMELYSIN;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL CULTURE; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CARCINOGENESIS; COCULTURE; CONTROLLED STUDY; DISEASE SEVERITY; FIBROBLAST; FIBROBLAST CULTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH VESSEL METASTASIS; METASTASIS; PANCREAS CARCINOMA; PANCREAS INVASIVE DUCTAL CARCINOMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR INVASION; VASCULAR INVASION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; COCULTURE TECHNIQUES; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84890445450     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-168     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004, 198:722-731. 10.1016/j.jamcollsurg.2004.01.008, 15110805.
3. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008, 68:918-926. 10.1158/0008-5472.CAN-07-5714, 2519173, 18245495.
4. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Canc 2006, 6:392-401.
5. Couvelard A, O'Toole D, Leek R, Turley H, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005, 46:668-676. 10.1111/j.1365-2559.2005.02160.x, 15910598.
6. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut 2011, 60:861-868. 10.1136/gut.2010.226092, 20966025.
7. Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, Pirola RC, Wilson JS. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 1998, 43:128-133. 10.1136/gut.43.1.128, 1727174, 9771417.
8. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grunert A, Adler G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998, 115:421-432. 10.1016/S0016-5085(98)70209-4, 9679048.
9. Erkan M, Adler G, Apte MV, Bachem MG, Buchholz M, Detlefsen S, Esposito I, Friess H, Gress TM, Habisch HJ, Hwang RF, Jaster R, Kleeff J, Kloppel G, Kordes C, Logsdon CD, Masamune A, Michalski CW, Oh J, Phillips PA, Pinzani M, Reiser-Erkan C, Tsukamoto H, Wilson J. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 2012, 61:172-178. 10.1136/gutjnl-2011-301220, 3245897, 22115911.
10. Masamune A, Watanabe T, Kikuta K, Shimosegawa T. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol 2009, 7:S48-54. 10.1016/j.cgh.2009.07.038, 19896099.
11. Habisch H, Zhou S, Siech M, Bachem MG. Interaction of stellate cells with pancreatic carcinoma cells. Cancers 2010, 2:1661-1682. 10.3390/cancers2031661, 3837330, 24281180.
12. Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Gastroenterology 2011, 141:1486-1497. 1497 e1481-1414, 10.1053/j.gastro.2011.06.047, 21704588.
13. Ikenaga N, Ohuchida K, Mizumoto K, Cui L, Kayashima T, Morimatsu K, Moriyama T, Nakata K, Fujita H, Tanaka M. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 2010, 139:1041-1051. 1051 e1041-1048, 10.1053/j.gastro.2010.05.084, 20685603.
14. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999, 154:385-394. 10.1016/S0002-9440(10)65285-6, 1849992, 10027397.
15. Matsui K, Breitender-Geleff S, Soleiman A, Kowalski H, Kerjaschki D. Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Nephrol Dial Transplant 1999, 14(Suppl 1):9-11.
16. Rishi AK, Joyce-Brady M, Fisher J, Dobbs LG, Floros J, VanderSpek J, Brody JS, Williams MC. Cloning, characterization, and development expression of a rat lung alveolar type I cell gene in embryonic endodermal and neural derivatives. Dev Biol 1995, 167:294-306. 10.1006/dbio.1995.1024, 7851650.
17. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005, 166:913-921. 10.1016/S0002-9440(10)62311-5, 1602360, 15743802.
18. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006, 19:34-48. 10.1038/modpathol.3800471, 16056246.
19. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer 2007, 96:1-5. 10.1038/sj.bjc.6603518, 2360213, 17179989.
20. Suzuki H, Onimaru M, Yonemitsu Y, Maehara Y, Nakamura S, Sueishi K. Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells. Mol Cancer 2010, 9:287. 10.1186/1476-4598-9-287, 2987985, 21034514.
21. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006, 107:563-569. 10.1002/cncr.22061, 16804930.
22. Xu Y, Ogose A, Kawashima H, Hotta T, Ariizumi T, Li G, Umezu H, Endo N. High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis. Oncol Rep 2011, 25:599-607.
23. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Canc Suppl J Int Canc Suppl 2013, 132:2339-2348.
24. Kaneko MK, Kato Y, Kitano T, Osawa M. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 2006, 378:52-57.
25. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, Fukayama M. Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol 2011, 179:1041-1049. 10.1016/j.ajpath.2011.04.027, 3157255, 21801875.
26. Scholl FG, Gamallo C, Vilaro S, Quintanilla M. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci 1999, 112(Pt 24):4601-4613.
27. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer cell 2006, 9:261-272. 10.1016/j.ccr.2006.03.010, 16616332.
28. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006, 119:4541-4553. 10.1242/jcs.03218, 17046996.
29. Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y, Tsuneyoshi M. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol 2008, 21:256-264. 10.1038/modpathol.3800985, 18192971.
30. Carvalho FM, Zaganelli FL, Almeida BGL, Goes JCS, Baracat EC, Carvalho JP. Prognostic value of podoplanin expression in intratumoral stroma and neoplastic cells of uterine cervical carcinomas. Clinics 2010, 65:1279-1283. 10.1590/S1807-59322010001200009, 3020337, 21340215.
31. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, Sasaki H, Ochiai A. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res 2011, 71:4769-4779. 10.1158/0008-5472.CAN-10-3228, 21610106.
32. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K, Ochiai A. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008, 123:1053-1059. 10.1002/ijc.23611, 18546264.
33. Kitano H, Kageyama S, Hewitt SM, Hayashi R, Doki Y, Ozaki Y, Fujino S, Takikita M, Kubo H, Fukuoka J. Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch Pathol Lab Med 2010, 134:1520-1527.
34. Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, Calik J, Wojnar A, Witkiewicz W, Rys J, Ugorski M, Dziegiel P, Podhorska-Okolow M. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 2011, 59:1249-1260. 10.1111/j.1365-2559.2011.04060.x, 22175904.
35. Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, Watanabe M, Hirohashi S. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology 2009, 77:53-62. 10.1159/000226112, 19556810.
36. Zhang Y, Tang H, Cai J, Zhang T, Guo J, Feng D, Wang Z. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett 2011, 303:47-55. 10.1016/j.canlet.2011.01.011, 21310528.
37. Exocrine and Endocrine Pancreas 2010, 241-248. New York: Springer, Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, 7, AJCC cancer staging manual.
38. Fujita H, Ohuchida K, Mizumoto K, Egami T, Miyoshi K, Moriyama T, Cui L, Yu J, Zhao M, Manabe T, Tanaka M. Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. Cancer Sci 2009, 100:2309-2317. 10.1111/j.1349-7006.2009.01317.x, 19735487.
39. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Canc 2002, 2:161-174.
40. Seiki M. The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr Opin Cell Biol 2002, 14:624-632. 10.1016/S0955-0674(02)00363-0, 12231359.
41. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. American journal of cancer research 2011, 1:482-497. 3186047, 21984967.
42. Madar S, Goldstein I, Rotter V. 'Cancer associated fibroblasts'-more than meets the eye. Trends Mol Med 2013, 19:447-453. 10.1016/j.molmed.2013.05.004, 23769623.
43. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147. 10.1016/j.ccr.2009.12.041, 20138012.
44. Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011, 11:245. 10.1186/1471-2407-11-245, 3141768, 21668992.
45. Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, Brindle KM, Teichmann SA, Tuveson DA, Fearon DT. Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 2013, 210:1137-1151. 10.1084/jem.20122344, 3674708, 23712428.
46. Fujita H, Ohuchida K, Mizumoto K, Nakata K, Yu J, Kayashima T, Cui L, Manabe T, Ohtsuka T, Tanaka M. Alpha-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas 2010, 39:1254-1262.
47. Hruban RH, Klöppel G, Boffetta P, Maitra A, Hiraoka N, Offerhaus GJA, Lacobuzio-Donahue C, Pitman MB, Kato Y, Kern SE, Klimstra DS. Ductal adenocarcinoma of the pancreas. WHO classification of tumours of the digestive system 2010, 281-291. World Health Organization.
48. Eguchi D, Ikenaga N, Ohuchida K, Kozono S, Cui L, Fujiwara K, Fujino M, Ohtsuka T, Mizumoto K, Tanaka M. Hypoxia enhances the interaction between pancreatic stellate cells and cancer cells via increased secretion of connective tissue growth factor. J Surg Res 2013, 181:225-233. 10.1016/j.jss.2012.06.051, 22795353.
49. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004, 64:3215-3222. 10.1158/0008-5472.CAN-03-2464, 15126362.
50. Iwamoto Y, Tanaka K, Okuyama K, Sugioka Y, Taniguchi S. In vitro assay of the invasive potential of malignant bone and soft tissue tumours through basement membranes. Int Orthop 1994, 18:240-247.